sj-docx-1-mso-10.1177_20552173231226106 - Supplemental material for Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital 
support programme

Hardy, TA; Aouad, P; Barnett, MH; Blum, S; Broadley, S; Carroll, WM; Crimmins, D; Griffiths, D; Hodgkinson, S; Lechner-Scott, J; Lee, A; Malhotra, R; McCombe, P; Parratt, J; Plummer, C; Van der Walt, A; Martel, K; Walker, RA

doi:10.25384/SAGE.24994046.v1

sj-docx-1-mso-10.1177_20552173231226106.docx (37.74 kB)

sj-docx-1-mso-10.1177_20552173231226106 - Supplemental material for Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme

journal contribution

posted on 2024-01-13, 09:02 authored by TA Hardy, P Aouad, MH Barnett, S Blum, S Broadley, WM Carroll, D Crimmins, D Griffiths, S Hodgkinson, J Lechner-Scott, A Lee, R Malhotra, P McCombe, J Parratt, C Plummer, A Van der Walt, K Martel, RA Walker

Supplemental material, sj-docx-1-mso-10.1177_20552173231226106 for Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme by TA Hardy, P Aouad, MH Barnett, S Blum, S Broadley, WM Carroll, D Crimmins, D Griffiths, S Hodgkinson, J Lechner-Scott, A Lee, R Malhotra, P McCombe, J Parratt, C Plummer, A Van der Walt, K Martel and RA Walker in Multiple Sclerosis Journal – Experimental, Translational and Clinical